Revvity, Inc. announced a collaboration with Eli Lilly and Company to broaden access to Lilly TuneLab by bringing the platform to the Revvity Signals ecosystem. The collaboration builds on Revvity’s recently launched Signals Xynthetica offering and aims to accelerate AI-enabled drug discovery through a federated learning approach.
Lilly TuneLab was designed to provide wider Lilly TuneLab access to advanced AI and machine learning models developed from long-term Lilly research efforts. Biotech organizations can use the models while contributing experimental data that enhances learning through federated approaches. Signals Xynthetica enables direct use of these models inside the Signals platform, where discovery teams already analyze data.
“Federated learning represents one of the most powerful paths forward for AI in drug discovery, but it requires the right platform to succeed,” said Kevin Willoe, president of Revvity Signals Software. “By providing access to Lilly’s worldclass predictive models through the Signals Xynthetica platform, we are creating a practical, secure way for organizations of all sizes to contribute to, and benefit from, collective intelligence.”
Proprietary data stays private and secure, while shared learning improves predictive performance. This setup is expected to boost the impact of data from small and midsized biotech companies, whose diverse experiments can help improve results for everyone.
The collaboration will allow participating organizations to leverage Lilly’s predictive models in their own discovery programs using Revvity’s Models-as-a-Service framework and its Signals Xynthetica offering. At the same time, their proprietary data remains private and secure while aggregated learning is used to improve predictive performance. The open model access and federated learning approach are expected to have an even greater impact on data contributions from small and mid-sized biotech companies, which typically have less data but can make meaningful contributions to shared outcomes due to the diversity of their experiments.
Signals provides core infrastructure needed to support Lilly TuneLab access, including scientific data management, analytics, and collaboration across internal teams and external partners. Signals One supports wet-lab data capture and experiment orchestration, while Signals Synergy enables secure data exchange with contract research organizations, academic collaborators and other external partners, all capabilities seen as essential to federated learning at scale.
As part of the agreement, Revvity and Lilly will jointly fund access to the collaboration for selected participants. This includes access to Signals One and Signals Xynthetica software offerings as well as modeling credits. The co-funded structure is intended to lower the cost of entry for interested organizations and reflects a shared focus by both companies on removing barriers to AI adoption and driving innovation across the biotech ecosystem.
